Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Rhea-AI Summary

Sensei Biotherapeutics (Nasdaq: SNSE) has announced its participation in two major scientific conferences. At PEGS Europe in Barcelona (November 5-7, 2024), Chief Scientific Officer Edward van der Horst will present on SNS-101, a conditionally active monoclonal antibody targeting VISTA in tumor microenvironment. At the SITC 39th Annual Meeting in Houston (November 6-10, 2024), Senior Director F. Donelson Smith will present a poster on spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications.

BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences.

Conference and Presentation Details:

PEGS Europe: Protein and Antibody Engineering Summit, November 5-7, 2024, Barcelona, Spain

Title: Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditionally Active Monoclonal Antibody
Presenter: Edward van der Horst, Ph.D., Chief Scientific Officer
Session: Antibody-Based Cancer Therapies
Date and time: Tuesday, November 5, 2024, 9:00 a.m. CET (Central European Time)

Society for Immunotherapy Cancer (SITC) 39^th Annual Meeting, November 6-10, Houston Texas

Title: Spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications
Presenter: F. Donelson Smith, Ph.D., Senior Director, Biologics Discovery & Early Development
Presentation Type: Poster
Abstract Number: 70
Date and Time: Saturday, November 9, 2024, 12:15–1:45 p.m. & 7:00-8:30 p.m. CST.
Location: Level 1-Exhibit Halls AB (George R. Brown Convention Center)

About Sensei Biotherapeutics  
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.  

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com

FAQ

When will Sensei Biotherapeutics (SNSE) present at PEGS Europe 2024?

Sensei Biotherapeutics will present at PEGS Europe on Tuesday, November 5, 2024, at 9:00 a.m. CET in Barcelona, Spain.

What will Sensei Biotherapeutics (SNSE) present at SITC 2024?

Sensei Biotherapeutics will present a poster (Abstract #70) on spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications.

What is SNS-101 that Sensei Biotherapeutics (SNSE) will discuss at PEGS Europe?

SNS-101 is a conditionally active monoclonal antibody that selectively targets VISTA in the tumor microenvironment.

Where and when will Sensei Biotherapeutics (SNSE) present at SITC 2024?

The presentation will take place on Saturday, November 9, 2024, from 12:15-1:45 p.m. & 7:00-8:30 p.m. CST at the George R. Brown Convention Center in Houston, Texas.